Erythropoietin is the major hormone regulator of erythrocyte production promoting the survival, as well as the differentiation and maturation, of erythroid progenitor cells. In addition to these well-characterized effects, it appears that an erythropoietin-responsive non-erythroid mechanism also mediates the selective destruction of young circulating erythrocytes (neocytes) when red cell mass becomes excessive – a process termed ‘neocytolysis’. Endothelial cells appear to respond to a rapid decrease in circulating levels of erythropoietin by secreting cytokines (including TGF-α), which signal reticuloendothelial phagocytes to destroy neocytes. The result is a more rapid decrease in red cell mass than can be explained by natural erythrocyte senescence alone. The current pharmacologic approach to treatment of anaemia in chronic kidney disease may cause neocytolysis and could keep therapy from reaching its full potential. Understanding neocytolysis and its relationship to fluctuating serum erythropoietin levels might help to better understand optimal treatment with erythropoietic agents.

Keywords:
Anaemia, Neocytolysis, Chronic kidney disease, Erythropoiesis-stimulating agents
1.
Parker PA, Izard MW, Maher JF: Therapy of iron deficiency anemia in patients on maintenance dialysis. Nephron 1979;23:181–186.
2.
Potasman I, Better OS: The role of secondary hyperparathyroidism in the anemia of chronic renal failure. Nephron 1983;33:229–231.
3.
Adamson JW, Eschbach JW: Management of the anaemia of chronic renal failure with recombinant erythropoietin. Q J Med 1989;73:1093–1101.
4.
Kaiser L, Schwartz KA: Aluminium-induced anemia. Am J Kidney Dis 1985;6:348–352.
5.
Hampers CL, Streiff R, Nathan DG, Snyder D, Merrill JP: Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 1967;276:551–554.
6.
Eschbach JW: The future of R-HuEPO. Nephrol Dial Transplant 1995;10(suppl 2): 96–109.
7.
Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, Pereira BJ: Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 2001;12:1501–1507.
8.
Alfrey CP, Rice L, Udden MM, Driscoll B: Neocytolysis: physiological down-regulator of red-cell mass. Lancet 1997;349:1389–1390.
9.
Rice L, Alfrey CP, Driscoll T, Whitely CE, Hachey DL, Suki W: Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 1999;33:59–62.
10.
Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578–583.
11.
Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439–446.
12.
Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003;64:1514–1521.
13.
Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111–124.
14.
Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM: Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005;46:481–488.
15.
Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337–1343.
16.
Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205–1210.
17.
Fishbane S: Recombinant human erythropoietin: has treatment reached its full potential? Semin Dial 2006;19:1–4.
18.
Williams WJ, Morris MW, Nelson DA: Examination of the blood; in Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds): Williams’ Hematology, ed 5. New York, McGraw-Hill, 1995, pp 8–15.
19.
Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, Ratcliffe PJ: Sites of erythropoietin production. Kidney Int 1997;51:393–401.
20.
Jelkmann W: Biochemistry and assays of EPO; in Jelkmann W (ed): Erythropoietin: Molecular Biology and Clinical Use. Johnson City/TN, FP Graham Publishing, 2003, pp 35–63.
21.
Maxwell P: HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003;14:2712–2722.
22.
Mulcahy L: The erythropoietin receptor. Semin Oncol 2001;28(suppl 8):19–23.
23.
Koury MJ, Sayer ST, Brandt S: New insights into erythropoiesis. Curr Opin Hematol 2002;9:93–100.
24.
Erlsev AJ, Besarab A: Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997;51:622–630.
25.
Polenakovic M, Sikole A: Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 1996;7:1178–1182.
26.
Koury M, Bondurant M: Erythropoietin retards DNA breakdown and prevents programmed cell death in erythroid progenitor cells. Science 1990;248:378–381.
27.
Broudy VC, Lin N, Brice M, Nakamoto B, Papyannopoulo T: Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991;77:2583–2590.
28.
Udden MM, Driscoll TB, Pickett MH, Leach-Huntoon CS, Alfrey CP: Decreased production of red blood cells in human subjects exposed to microgravity. J Lab Clin Med 1995;125:442–449.
29.
Alfrey CP, Udden MU, Leach-Huntoon C, Driscoll T, Pickett MH: Control of the red blood cell mass in spaceflight. J Appl Physiol 1996;81:98–104.
30.
Rice L, Alfrey CP: The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005;15:245–250.
31.
Trial J, Rice L: Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Design 2004;10:183–190.
32.
Rice L, Ruiz W, Driscoll T, Whitely CE, Tapia R, Hachey DL, Gonzales GF, Alfrey CP: Neocytolysis on descent from altitude: a newly recognized mechanism for the control of red cell mass. Ann Intern Med 2001;134:652–656.
33.
Trial J, Rice L, Alfrey CP: Erythropoietin withdrawal alters interactions between young red blood cells, splenic endothelial cells, and macrophages: an in vitro model of neocytolysis. J Investig Med 2001;49:335–345.
34.
Halstenson CE, Macres M, Katz SA, Schneiders JR, Watanabe M, Sobota JT, Abraham PA: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702–712.
35.
Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392–2395.
36.
Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E: Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992;2:1405–1416.
37.
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006;47(suppl 3):S11–S145.
38.
Macdougall IC, Wilson P, Roche A: Impact of haemoglobin variability in haemodialysis patients receiving erythropoiesis-stimulating agents for the management of renal anaemia. J Am Soc Nephrol 2005;16:899A (abstr PUB541).
39.
Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ: Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004;19:898–903.
40.
Disney A: Aranesp® (darbepoetin alfa) administered once monthly (QM) maintains hemoglobin (Hb) levels in chronic kidney disease (CKD) patients. Nephrol Dial Transplant 2005;20(suppl 5):v254 (abstr MP164).
41.
Ling B, Walczyk M, Agarwal A, Carrol W, Lui W, Brenner R: Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005;63:327–334.
42.
Provenzano R, Bhaduri S, Singh AK, for the PROMPT Study Group: Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;2:113–123.
43.
Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C: An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 2006;260:577–585.
44.
Dougherty FC, Reigner B, Jordan P, Pannier A: CERA (continuous erythropoiesis receptor activator): dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies. Proc Am Soc Clin Oncol 2004;23:603 (abstr 6692).
45.
Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B: Pharmacokinetics and pharmcodynamics of intravenous and subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211–1215.
46.
Macdougall IC, Reigner B, Dougherty FC: Consistent pharmacokinetic properties of CERA (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD. Am J Kidney Dis 2006;47:89.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.